Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

743
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
743
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

948
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
948
Cardiac Catheterization I: Pre-Procedure Overview01:28

Cardiac Catheterization I: Pre-Procedure Overview

2.4K
Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...
2.4K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.8K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.8K
Drugs Acting on Autonomic Ganglia: Stimulants01:23

Drugs Acting on Autonomic Ganglia: Stimulants

2.2K

Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
2.2K
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

2.5K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multidisciplinary management of X-linked myotubular myopathy in Spain and Portugal: A case series analysis.

Neurologia·2026
Same author

Clinical practice guidelines for the diagnosis and management of Charcot-Marie-Tooth disease.

Neurologia·2024
Same author

Clinical guide for the diagnosis and follow-up of myotonic dystrophy type 1, MD1 or Steinert's disease.

Neurologia·2019
Same author

European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience.

European journal of neurology·2017
Same author

Significance of tuber size for complications of tuberous sclerosis complex.

Neurologia (Barcelona, Spain)·2013
Same author

[Congenital cytomegalovirus infection and cortical/subcortical malformations].

Neurologia (Barcelona, Spain)·2012

Related Experiment Video

Updated: Mar 26, 2026

Author Spotlight: Innovative Methods in Lymphedema and Hypertension Research
08:46

Author Spotlight: Innovative Methods in Lymphedema and Hypertension Research

Published on: March 22, 2024

1.7K

[Nicardipine-induced gingival hyperplasia]

I Pascual-Castroviejo1, S I Pascual Pascual

  • 1Servicio de Neurología Pediátrica, Hospital Infantil La Paz, Madrid.

Neurologia (Barcelona, Spain)
|January 1, 1997
PubMed
Summary

This case study reports the first instance of nicardipine-induced gingival hyperplasia in a pediatric patient. The 8.5-year-old boy developed this side effect after long-term nicardipine treatment for cerebrovascular disease.

Area of Science:

  • Pharmacology
  • Oral Medicine
  • Pediatric Neurology

Background:

  • Drug-induced gingival hyperplasia is a known side effect of certain medications, including hydantoins, cyclosporine, and some calcium channel blockers.
  • These effects are typically observed in adults or the elderly, with limited reports in pediatric populations.

Observation:

  • An 8.5-year-old boy with cerebrovascular disease was treated with nicardipine for over 5 years starting at 20 months of age.
  • Following a dose increase from 40 to 50 mg/day, the patient developed progressive gingival hyperplasia over two years.
  • No other medications were administered concurrently or historically.

Findings:

  • This report details the first documented case of nicardipine-induced gingival hyperplasia in a child.
  • The hyperplasia developed after a dose escalation of nicardipine, suggesting a dose-dependent relationship.

More Related Videos

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

2.2K
A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application
06:53

A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application

Published on: July 9, 2020

5.7K

Related Experiment Videos

Last Updated: Mar 26, 2026

Author Spotlight: Innovative Methods in Lymphedema and Hypertension Research
08:46

Author Spotlight: Innovative Methods in Lymphedema and Hypertension Research

Published on: March 22, 2024

1.7K
Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

2.2K
A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application
06:53

A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application

Published on: July 9, 2020

5.7K

Implications:

  • This finding expands the known side effect profile of nicardipine to include gingival hyperplasia in pediatric patients.
  • Clinicians should consider nicardipine as a potential cause of gingival hyperplasia in children, especially with increased dosages.
  • Further research is warranted to understand the mechanism and prevalence of nicardipine-induced gingival hyperplasia in pediatric populations.